Commentary: Aligning Incentives to Fulfill the Promise of Personalized Medicine
Precision’s Dana Goldman and Senior Research Economist Karen Van Nuys, along with co-authors Victor J Dzau, Geoffrey S Ginsburg and David Agus, address new developments in personalized medicine.
Commentary: Non-Adherence in Healthcare: Are Patients or Policymakers Ill-Informed?
Precision’s Tomas Philipson in his regular column in Forbes.com, talks about the precision medicine initiative as a more useful approach towards appropriate adherence behavior.
Exploring Precision Medicine’s Value – Managed Healthcare Executive
In the May cover story: “Exploring Precision Medicine’s Value” Dan Renick discusses the value of specialized treatments. He contends that precision medicine in the face of limited resources necessitates evidence generation that supports the value of therapeutic breakthroughs. The in-depth article explores the value of precision medicine from a research, governmental and managed care perspective
Commentary: It’s Time for Value-Based Payment In Oncology
In Health Affairs, PHE’s Goldman and Lakdawalla suggest it’s time for value-based payment in oncology.
Congressional Budget Office Leader James Baumgardner, PhD, Joins Precision
Los Angeles, CA, April 27, 2015—Precision Health Economics (PHE), a Precision for Medicine company, announced today the hiring of James Baumgardner, PhD, as Senior Research Economist. Joining PHE from his post as Deputy Assistant Director in the Health, Retirement, and Long-Term Analysis Division of the Congressional Budget Office (CBO), Mr. Baumgardner brings unique experiences and perspectives to the complex and challenging problems PHE addresses in its work on health economics and policy. PHE is focused on the critical issues in health and healthcare delivery: objective determination of value and measureable improvement in patient outcomes.